Asthmatic subjects who are resident at altitude may experience a deterioration in lung function following a stay at sea level. To determine whether measurement of urinary leukotriene E4 (LTEJ reflects changes in asthma severity and airway responsiveness, 14 allergic asthmatic subjects resident at altitude (1560 m, Davos, Switzerland) were studied.
The cysteinyl leukotrienes (LTC4, LTD4 and LTE4) are derived from arachidonic acid by the action of 5lipoxygenase, which generates 5-hydroperoxyeicosatetraenoic acid and then leukotriene A4 (LTA4) [1] [2] [3] . LTA4 is metabolized by the addition of glutathione to form LTC4. LTC4 may be converted by y-glutamyltranspeptidase to generate LTD4, which is converted by a di peptidase to yield LTE4 [4, 5] . In vitro the cysteinyl leukotrienes, LTC4, LTD4 and LTE4, contract smooth muscle and enhance micro vascular permeability [6] [7] [8] . In humans they are potent bronchoconstrictor agents when inhaled, and increase nonspecific bronchial hyper responsiveness [9] [10] [11] [12] .
In man, there is rapid metabolism of LTC4 to LTD4 and then to LTE4. LTE4 may be further metabolized to oxidation products, which are excreted into bile and urine [13] [14] [15] [16] . Combined reversed-phase high performance liquid chromatography (RP-HPLC) and radioimmuno assay (RIA) enables urinary LTE4 to be measured [17] , and the values have been used as an estimate of the pro duction of cysteinyl leukotrienes in vivo. An increase in LTE4 excretion occurs during an acute exacerbation of asthma, after antigen challenge in allergic asthmatic subjects [18] [19] [20] [21] [22] , and following aspirin-induced asthma [23] . Antigen-induced bronchoconstriction is attenuated by prior treatment with leukotriene receptor antagonist [24, 25] , supporting a role for the cysteinyl leukotrienes in acute allergic bronchoconstriction. The improvement in basal lung function after ingestion of an oral active LTD4 receptor antagonist [26] , and improvement of pul monary lung function following long-term administra tion of leukotriene receptor antagonists [27] , supports a role for the cysteinyl leukotrienes in influencing basal bronchial tone.
Residence at altitude may be beneficial for subjects with atopic asthma, possibly due to the low concentra tion of house dust mite antigen [28, 29] . A deteriora tion in lung function may be observed on return to sea level, and this has been attributed to the increased expo sure to allergen(s) and pollutants [28] [29] [30] [31] , This study involved asthmatic children who were resident at The Netherlands Asthma Centre at altitude, since it had been observed that a return to The Netherlands may be ac companied by a deterioration in lung function.
To assess whether the deterioration in lung function in atopic asthmatic subjects residing at altitude after transient exposure to low altitude is accompanied by elevations in urinary LTE4, we have measured urinary LTE4 in eight asthmatic subjects normally resident at altitude who returned to sea level for a short visit and six asthmatic subjects resident at altitude over a similar period of time.
Methods

Subjects
Fourteen asthmatic subjects were studied (table 1) . Asthma was defined by a history of episodic wheezing and a >20% reversibility of resting FEVj following 400 (ig inhaled albuterol. Atopic asthmatic subjects demon strated a >3 mm wheal as compared to the diluent con- trol in response to skin-prick tests to at least two com mon aeroallergens: grass pollen, tree pollen, cat dander, dog hair, Dermatophagoides pteronyssinus and D. farime. All subjects were positive to house dust mite extracts. Subjects had not taken antihistamines in the month prior to the study, and no subject had experienced an upper respiratory tract infection in the preceding month, or during the study. The study protocol was approved by The Netherlands Asthma Centre Hospital Ethics Com mittee, and written informed consent was provided by the parent of each subject studied.
Study protocol
The Netherlands Asthma Centre in Davos is a clinic at moderate altitude (1,560 m) . Asthmatic children may stay for up to 9 months and during this time return to The Netherlands for a short visit. In a prospective, ran domized fashion, mild asthmatic subjects who had been resident in The Netherlands Asthma Centre, Davos, Switzerland (1,560 m) for at least one month, were selec ted to participate in the study following a full clinical history, examination and skin-prick tests to common inhaled aeroallergens. Subjects were randomly divided into two groups. During the same month, one group remained in Davos, whilst the second group returned to The Netherlands (360 m) for 14 days and then returned to Davos. All subjects attended the laboratory on two separate study days at the same time of day. In asth matic subjects who remained in Davos, the study days were separated by 3 weeks, whereas in the group of asth matic subjects who returned to The Netherlands, the study days were performed within 48 h of leaving for The Netherlands and within 48 h of returning to Davos. Medication was withheld for 8 h prior to each study day. On each study day, blood was withdrawn for total IgE measurement and eosinophil count. A urine sample was collected for LTE4 measurement, and then, within one hour, a histamine inhalation challenge was perfor med. Two subjects refused blood sampling on the sec ond study day, One further subject selected in addition to the 14 participating in the study was excluded from the study, since medication was altered between the 2 study days when the subject returned to The Netherlands and maintenance therapy with steroids was changed. There was no change in medication between the two study days in the other asthmatic subjects studied.
Histamine inhalation challenge was performed using the Asthma Provocation System (APS) dosimeter (Jaeger, Wuzzburg, Germany), which delivers compressed air at a pressure of 1.6 bar (22.8 psi) for a duration of 0.6 s from the start of each breath. Under these conditions, the nebulizer delivers droplets with a mass median aero dynamic diameter of 1.9 |jm. The output of the nebuli zer is 9.3 lil-breath*1. Measurements of FEVj were made using a Jaeger Masterlab Spirometer. Three measure ments of ¥EV{ were made at each time-point and the mean value was recorded. Provided baseline FEVl was greater than 70% predicted for the patient, inhalation challenge proceeded. Each inhalation started at functional residual capacity and terminated at approximately 70% baseline vital capacity; a 5 s breathhold was maintained at the end of each inhalation. Subjects inhaled control solution (five breaths of normal saline). FEVj mea surements were made at 1 and at 3 min after each inhala tion. If the decrease in FEV, was <10% baseline value, subjects underwent inhalation challenge with histamine. Serial twofold increasing concentrations of histamine diphosphate (Leiden University Hospital, Leiden, The Netherlands) were inhaled from a concentration of 0.03 mg'inl-1 up to a maximum concentration of 32 mg-ml*1. Doubling concentrations of histamine were administered until the FEV, had fallen by >20% baseline value. The provocation concentration of histamine producing a 20% fall in FEV, (PC20FEVj) was determined from the log concentration histamine response curve by linear inter polation.
M easurem ent o f urinary LTE4
Urine was collected prior to inhalation of histamine. The volume of urine was recorded and a 50 ml aliquot saved. The free radical scavenger, 4 hydroxy-2,2,6,6tetramethyl-l-piperidino-oxy free radical (4-hydroxy TEMPO; Aldrich Chemical Co., Milwaukee, WI, USA) was added at a final concentration of 1 mM, and the samples adjusted to pH 9.0 with NaOH to stabilize en dogenous leukotriene metabolites. The samples were coded and stored at -70°C until measurements of LTE4 were performed by RP-HPLC and RIA, as described pre viously [17] . 
Statistical analysis
in subjects returning to The Netherlands and those sub jects remaining in Davos, respectively. In the group of subjects who returned to The Nether lands, there was a significant decrease in FEVj on return to Davos from 3.0±0,3 to 2.8±0.3 I (mean±sEM) (p=0.04). In subjects who remained in Davos, there was no sig nificant difference in FEV! which was 2.9+0.3 and 2.9± 0.4 / (p=0.35) on study day one and study day two, respectively ( fig. 1 and table 2 ).
Values for urinary LTE4 and PC20FEV, histamine were logarithmically transformed prior to analysis, and the results were expressed as geometric mean (gm). For PC20FEV, histamine, statistical analysis was only per formed on subjects in whom a PC20FEV, histamine was determined. The Wilcoxon samples test was used to compare FEV1? urinary LTE4 and PC20FEV, histamine between the two groups of subjects on study day one, and the changes in FEVP urinary LTE4, PC20FEV, his tamine, total IgE, and eosinophil count between study day one and two in each group of asthmatic subjects. The relationship between urinary LTE4 and FEVj, PC20FEVj histamine, total IgE and eosinophil count in the subjects was analysed using Pearsons correlation coefficient.
Results
Lung function
The FEV, values for individual subjects in the two groups on study day one are shown in figure 1 and table 2. There was no significant difference between the base line FEV, in the two groups of asthmatic subjects stud ied, being 3.0±0.3 / (mean±SEM) and 2.9±0.3 / (p=0.9)
A irw ay response to histam ine
The PC20FEVj histamine in individual subjects on the two study days are shown in figure 2 and table 2. Sub ject No. 7 (study day 1) and No. 8 (study day 1 and 2) (table 2) did not respond with a 20% fall in FEV, after the maximum dose of histamine was administered. Hista mine challenge was not performed in subject No. 14 because he had a resting FEV, <65% of predicted FEV, on study day one and two. There was no significant dif ference in PC20FEV, histamine on study day one bet ween the two groups of asthmatic subjects. The PC20FEV, histamine was 1.7 mg-ml*1 (gm, range 0.3-16.4 mg-ml*1) (n=5) and 1.5 mg-mh1 (gm, range 0.3-22 mg-ml-1) (n=5) (p=0.5) in asthmatic subjects returning to The Netherlands and those subjects remaining in Davos, respectively. There was a significant decrease in PC20FEV, histamine from 1.7 mg-ml'1 (gm, range 0.3-16.4 mg-ml*1) to 0.9 mg-ml*1 (gm, range 0.1-5.2 mg-ml"1) (p=0.04) (n=5) fol lowing a 14 day visit to The Netherlands. In subjects who remained in Davos, there was no significant dif ference in PC20FEV, histamine, which was 1.5 mg-ml*1 (gm, range 0.3-22 mg-ml-1) and 1.5 mg-ml4 (gm, range 0.3-32 mg-ml1) (p=0.89) (n=5) on study day one and two, respectively. 
Urinary LTE4 concentration
There was no significant difference between the uri nary LTE4 concentration on study day one between the two groups of asthmatic subjects. The LTE4 concentra tion was 16.9 pg-mgA creatinine ( g m , range 0.3-101. There was a significant increase in urinary LTE4 con centration in the group of subjects returning to Davos from The Netherlands, from a baseline value of 16.9 pg-mg*1 creatinine (g m , range 0.3-101.7 pg-mg-1 creati nine) to 52.3 pg-mg*1 creatinine ( g m , range 8.8-301.6 pg-mg-1 creatinine) (p=0.04) ( fig. 3 and table 2 ). In con trast, there was no significant difference in urinary LTE4 concentration in subjects resident in Davos, whose urinary LTE4 concentration on study day 1 and 2 were 14.9 pg*mg-1 creatinine (g m , range 5.9-41.9 pg-mg1 cre atinine) and 12.0 pg-mg1 creatinine ( g m , range 5.1-25 pg-mg-1 creatinine) (p=0.24), respectively. 
IgE and eosinophil count
The total IgE level and eosinophil count in individual subjects is shown in table 3. There was no significant difference in total IgE levels or eosinophil counts in either group of subjects studied.
There was no significant correlation between urinary LTE4 and FEVj (r=0. 25 
Discussion
This study demonstrates that in 6 out of 8 allergic asth matic children resident at altitude who returned briefly to sea level and then returned to altitude, there was a decline in baseline FEV, and an increase in airway res ponsiveness to histamine. These changes were accom panied by an increase in urinary LTE4 excretion. The range of LTE4 concentration on study day one in our subjects was similar to that observed previously in adult asthmatic subjects [20, 32] , suggesting that there is no age-related difference in the range of LTE4 concentra tion during stable asthma and in the absence of other disease. A raised baseline urinary LTE4 is suggestive of aspirin-sensitive asthma [23] , but there was no clinical history of aspirin sensitivity or other distinguishing clini cal features in subject No. 6 who had a baseline urinary LTE4 higher than the other subjects.
After a 2 week stay in The Netherlands, LTE4 excre tion increased up to approximately threefold, in associ ation with a decrease in baseline FEV, and an increase in airway reactivity to histamine. This was not observed in subjects Nos. 4 and 5, who did not demonstrate a change in FEV! or PC20FEV, histamine between the two study days. The cause of this heterogeneity in response is unknown, but may reflect the variation of reactions in asthmatic subjects to environmental factors. Medication was withheld for 8 h prior to FEV, measurements, urine collections and histamine challenge and there was no change in medication between the two study days. In healthy subjects, R ic h a l e t et al. [33] observed that acute altitude hypoxia is associated with an increase in plas ma LTB4. An increase in leukotriene excretion during acute asthma in adult subjects has been reported by T a y l o r et a i [19] . A threefold increase in leukotriene excretion has also been reported following antigen and aspirin challenge in asthmatic subjects [19, 23] .
LTE4 concentration may be used to reflect systemic and pulmonary release of cysteinyl leukotrienes [31] . The increase in leukotriene excretion during a deterio ration of lung function reflects an increase in cysteinylleukotriene biosynthesis. The cysteinyl leukotrienes may have a central role in the pathogenesis of asthma, as sug gested by their recovery from the bronchoalveolar fluid of asthmatic subjects [32] , activity as potent lung spasmogens, and ability to increase airway hyperresponsive ness [10] [11] [12] . Their presence may explain the decrease in lung function and increase in airway responsiveness to histamine observed in our subjects after a brief visit to The Netherlands. Consistent with prior studies, we were unable to correlate circulating mediator levels of leukotrienes, FEV, measurement or airway reactivity to histamine [32] . At altitude, the concentration of house dust mite allergen is reduced [27, 30] , and it has been suggested that it is the decreased exposure to house dust mite which accounts for the improvement of lung func tion in allergic asthmatic subjects after a stay at altitude. All our subjects were sensitive to house dust mite aller gen on skin-prick testing, and it is possible that increased allergen exposure to house dust mite after return to sea level resulted in the deterioration of lung function. Other allergens and irritants, such as pollutants and other fac tors which change with altitude (humidity, temperature, barometric pressure), should also be considered. There was no difference in total IgE level between the two study days in subjects returning to The Netherlands, although changes may not be apparent during this short period of time. Whilst specific IgE against house dust mite was not determined during the study period in our subjects, dust mite allergen concentration from bedrooms at the Asthma Centre in Davos is low and in the region of 18 ng'g~* dust.
We did not detect a difference in blood eosinophil counts in subjects returning to The Netherlands. This is similar to the study of B o n e r et al. [34] , where the influ ence of allergen avoidance at altitude on serum markers of eosinophil activation in children with allergic asthma was investigated. Whilst there was no increase in peri pheral eosinophil count during allergen exposure, there was activation of eosinophils as indicated by the increase of eosinophil cationic protein (ECP) and eosinophil protein X (EPX) serum markers. It is possible that part of the increase in cysteinyl leukotrienes was due to eosi nophil activation during exposure to allergen in subjects returning to The Netherlands. The involvement of other cells, such as monocytes or mast cells, as a source for leukotriene synthesis was not determined in this study.
With the exception of subject No. 14, on study day one, all subjects had controlled asthma with FEVt mea surement >70% of predicted. A decrease in FEV1 mea surement was not observed in all subjects returning to Davos from The Netherlands. Whilst clinical severity could have been additionally assessed using peak flow readings and symptom scores, this was not possible due to poor compliance with completing peak flow charts and symptom questionnaires in the subjects. In this regard, parents were questioned about any changes in medication during the study period. Airway reactivity was assessed using PC20FEVj histamine, which is used routinely in The Netherlands Asthma Centre. In sub jects Nos 7 and 8, airway reactivity to histamine on study day one was >32 mg-mH These subjects had a history of asthma and a PC20FEVj histamine <8 mg-ml'1 on ad mission to the clinic 4 weeks prior to the study. An im provement in lung function and airway reactivity within a week of residence at altitude has previously been ob served in altitude clinics. For this reason, the study was conducted after the subjects had been resident for one month at altitude, to optimize stable control of asthma.
In conclusion, utilizing a novel design to provoke a minor deterioration in asthma through a change in the natural environment, we have demonstrated that a decrement in FEVl and an increase in airways respon siveness are accompanied by augmented biosynthesis of the cysteinyl leukotrienes. These results add further sup port to the need to test leukotriene receptor antagonists or biosynthesis inhibitors in the treatment of asthma.
